MET Amplification Clinical Trials

6 recruitingLast updated: June 17, 2026

There are 6 actively recruiting met amplification clinical trials across 15 countries. Studies span Phase 2, Phase 1. Top locations include Madrid, Spain, Los Angeles, California, United States, Beverly Hills, California, United States. Updated daily from ClinicalTrials.gov.


MET Amplification Trials at a Glance

6 actively recruiting trials for met amplification are listed on ClinicalTrialsFinder across 6 cities in 15 countries. The largest study group is Phase 2 with 6 trials, with the heaviest enrollment activity in Madrid, Los Angeles, and Beverly Hills. Lead sponsors running met amplification studies include AbbVie, Apollomics Inc., and Guangdong Provincial People's Hospital.

Browse met amplification trials by phase

Treatments under study

About MET Amplification Clinical Trials

Looking for clinical trials for MET Amplification? There are currently 5 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new MET Amplification trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about MET Amplification clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 16 of 6 trials

Recruiting
Phase 2

A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan

Solid Tumors Harboring MET Amplification
AbbVie100 enrolled33 locationsNCT07196644
Recruiting
Phase 2

Osimertinib Combined With Savolitinib in the Treatment of NSCLC With Low Copy Number MET Amplification

EGFR Positive Non-small Cell Lung CancerMET Amplification
Qingdao Central Hospital60 enrolled1 locationNCT07322783
Recruiting
Phase 2

APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

Pancreatic CancerGastric CancerLung Cancer+15 more
Apollomics Inc.497 enrolled35 locationsNCT03175224
Recruiting
Phase 2

Study of Crizotinib for ROS1 and MET Activated Lung Cancer

Stage IV Non-Small Cell Lung CancerMET AmplificationNon-squamous Non-small Cell Lung Cancer+2 more
University Health Network, Toronto50 enrolled1 locationNCT04084717
Recruiting
Phase 1Phase 2

The Efficacy and Safety of LMV-12 Combined With Osimertinib in NSCLC

Non-small Cell Lung CancerMET AmplificationEGF-R Positive Non-Small Cell Lung Cancer+1 more
Hunan Province Tumor Hospital120 enrolled1 locationNCT06109558
Recruiting
Phase 2

Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLC

Non-small Cell Lung CancerMET AmplificationBRAF V600 Mutation+3 more
Guangdong Provincial People's Hospital30 enrolled1 locationNCT05800340